tetano
Editor, Senior Moderator
Infez Med. 2020 Ahead Of Print Jun 1;28(2):174-184.
SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview
Rabaan AA[SUP]1[/SUP], Al-Ahmed SH[SUP]2[/SUP], Haque S[SUP]3[/SUP], Sah R[SUP]4[/SUP], Tiwari R[SUP]5[/SUP], Malik YS[SUP]6[/SUP], Dhama K[SUP]7[/SUP], Yatoo MI[SUP]8[/SUP], Bonilla-Aldana DK[SUP]9[/SUP], Rodriguez-Morales AJ[SUP]10[/SUP].
Author information
Abstract
The recent outbreak of SARS-CoV-2 that started in Wuhan, China, has now spread to several other countries and is in its exponential phase of spread. Although less pathogenic than SARS-CoV, it has taken several lives and taken down the economies of many countries. Before this outbreak, the most recent coronavirus outbreaks were the SARS-CoV and the MERS-CoV outbreaks that happened in China and Saudi Arabia, respectively. Since the SARS-CoV-2 belongs to the same family as of SARS-CoV and MERS-CoV, they share several similarities. So, this review aims at understanding the new scenario of SARS-CoV-2 outbreak and compares the epidemiology, clinical presentations, and the genetics of these coronaviruses. Studies reveal that SARS-CoV-2 is very similar in structure and pathogenicity with SARS-CoV, but the most important structural protein, i.e., the spike protein (S), is slightly different in these viruses. The presence of a furin-like cleavage site in SARS-CoV-2 facilitates the S protein priming and might increase the efficiency of the spread of SARS-CoV-2 as compared to other beta coronaviruses. So, furin inhibitors can be targeted as potential drug therapies for SARS-CoV.
PMID:32275259
Free full text
SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview
Rabaan AA[SUP]1[/SUP], Al-Ahmed SH[SUP]2[/SUP], Haque S[SUP]3[/SUP], Sah R[SUP]4[/SUP], Tiwari R[SUP]5[/SUP], Malik YS[SUP]6[/SUP], Dhama K[SUP]7[/SUP], Yatoo MI[SUP]8[/SUP], Bonilla-Aldana DK[SUP]9[/SUP], Rodriguez-Morales AJ[SUP]10[/SUP].
Author information
Abstract
The recent outbreak of SARS-CoV-2 that started in Wuhan, China, has now spread to several other countries and is in its exponential phase of spread. Although less pathogenic than SARS-CoV, it has taken several lives and taken down the economies of many countries. Before this outbreak, the most recent coronavirus outbreaks were the SARS-CoV and the MERS-CoV outbreaks that happened in China and Saudi Arabia, respectively. Since the SARS-CoV-2 belongs to the same family as of SARS-CoV and MERS-CoV, they share several similarities. So, this review aims at understanding the new scenario of SARS-CoV-2 outbreak and compares the epidemiology, clinical presentations, and the genetics of these coronaviruses. Studies reveal that SARS-CoV-2 is very similar in structure and pathogenicity with SARS-CoV, but the most important structural protein, i.e., the spike protein (S), is slightly different in these viruses. The presence of a furin-like cleavage site in SARS-CoV-2 facilitates the S protein priming and might increase the efficiency of the spread of SARS-CoV-2 as compared to other beta coronaviruses. So, furin inhibitors can be targeted as potential drug therapies for SARS-CoV.
PMID:32275259
Free full text